机构：[1]Department of Geriatric Cardiology, General Hospital of Southern Theater Command, People's Liberation Army, Guangzhou 510010, China.[2]Graduate School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.[3]Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences and the Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou 511436, China.[4]School of Chemistry and Chemical Engineering, Guangdong Pharmaceutical University, Guangzhou 510006, China.[5]Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou 510515, China.
Chemotherapy-induced side effects restrain anti-tumor efficiency, with hyperlipidemia being the most common accompanying disease to cause treatment failure. In this work, a chimeric peptide-engineered nanomedicine (designated as PRS) was fabricated for the synergistic suppression of tumor growth and therapy-induced hyperlipidemia. Within this nanomedicine, the tumor matrix-targeting peptide palmitic-K(palmitic)CREKA can self-assemble into a nano-micelle to encapsulate Rapamycin (mTOR inhibitor) and SBC-115076 (PCSK9 inhibitor). This PRS nanomedicine exhibits a uniform nano-distribution with good stability which enhances intracellular drug delivery and tumor-targeting delivery. Also, PRS was found to synergistically inhibit tumor cell proliferation by interrupting the mTOR pathway and reducing Rapamycin-induced hyperlipidemia by increasing the production of LDLR. In vitro and in vivo results demonstrate the superiority of PRS for systematic suppression of tumor growth and the reduction of hyperlipidemia without initiating any other toxic side effects. This work proposes a sophisticated strategy to inhibit tumor growth and also provides new insights for cooperative management of chemotherapy-induced side effects.
基金：
This research was funded by Science and Technology Projects in Guangzhou (Grant
Number: 2023A03J0170) and the Guangdong Basic and Applied Basic Research Foundation (Grant
Number: 2021B1515020043).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|2 区医学
小类|2 区药学
最新[2025]版：
大类|3 区医学
小类|3 区药学
第一作者：
第一作者机构：[1]Department of Geriatric Cardiology, General Hospital of Southern Theater Command, People's Liberation Army, Guangzhou 510010, China.[2]Graduate School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
共同第一作者：
通讯作者：
通讯机构：[1]Department of Geriatric Cardiology, General Hospital of Southern Theater Command, People's Liberation Army, Guangzhou 510010, China.[2]Graduate School, Guangzhou University of Chinese Medicine, Guangzhou 510006, China.
推荐引用方式(GB/T 7714)：
Cai Hua,Zheng Rongrong,Wu Ningxia,et al.Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition[J].Pharmaceutics.2023,15(10):doi:10.3390/pharmaceutics15102377.
APA：
Cai Hua,Zheng Rongrong,Wu Ningxia,Hu Jiaman,Wang Ruixin...&Xu Lin.(2023).Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition.Pharmaceutics,15,(10)
MLA：
Cai Hua,et al."Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition".Pharmaceutics 15..10(2023)
